GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » Days Sales Outstanding

CPIX (Cumberland Pharmaceuticals) Days Sales Outstanding : 100.61 (As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Cumberland Pharmaceuticals Days Sales Outstanding?

Cumberland Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2024 was $11.51 Mil. Cumberland Pharmaceuticals's Revenue for the three months ended in Dec. 2024 was $10.44 Mil. Hence, Cumberland Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2024 was 100.61.

The historical rank and industry rank for Cumberland Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

CPIX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.06   Med: 92.36   Max: 106.09
Current: 106.09

During the past 13 years, Cumberland Pharmaceuticals's highest Days Sales Outstanding was 106.09. The lowest was 63.06. And the median was 92.36.

CPIX's Days Sales Outstanding is ranked worse than
75.55% of 961 companies
in the Drug Manufacturers industry
Industry Median: 72.25 vs CPIX: 106.09

Cumberland Pharmaceuticals's Days Sales Outstanding declined from Dec. 2023 (109.16) to Dec. 2024 (100.61).


Cumberland Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Cumberland Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cumberland Pharmaceuticals Days Sales Outstanding Chart

Cumberland Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 98.64 97.65 87.06 105.76 103.42

Cumberland Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 109.16 109.55 103.15 115.15 100.61

Competitive Comparison of Cumberland Pharmaceuticals's Days Sales Outstanding

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cumberland Pharmaceuticals's Days Sales Outstanding Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's Days Sales Outstanding falls into.


;
;

Cumberland Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Cumberland Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2024 is calculated as

Days Sales Outstanding (A: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (9.758 + 11.701) / 2 ) / 37.868*365
=10.7295 / 37.868*365
=103.42

Cumberland Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding (Q: Dec. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Sep. 2024 ) + Accounts Receivable (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )*Days in Period
=( (11.311 + 11.701) / 2 ) / 10.436*365 / 4
=11.506 / 10.436*365 / 4
=100.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cumberland Pharmaceuticals  (NAS:CPIX) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Cumberland Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Cumberland Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Executives
A J Kazimi director, 10 percent owner, officer: Chairman and CEO 1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Kenneth Krogulski director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
James Jones director 2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Todd M. Anthony officer: Vice Pres Organizational Dev 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman officer: Vice Pres Sales & Marketing 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante director 111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
Brown Martin S Jr director 850 DIXIE HIGHWAY, LOUISVILLE KY 40210
Martin E Cearnal director 31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard officer: Senior Vice President 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs director 830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence director 1880 ELLINGTON WAY, AUBURN AL 36830